Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $12 to $7.
Stocks · News reference
LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst
LENZ Therapeutics partners with Arrotex to commercialize VIZZ in Australia and New Zealand as analysts remain focused on U.S. growth.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report
LENZ Therapeutics Q2 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.486M Beat $2.373M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.06) by 3.77 percent. This is a 92.45 percent decrease over losses of $(0.53) per share from
LENZ Therapeutics Announces Availability Of VIZZ Through Telehealth Platform